WILMINGTON, Mass., Oct. 16, 2015 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced the following executive promotions:
- Todd Silvestri, formerly Implant's Vice President of Technology, has been promoted to Chief Operating Officer; and
- Dr. Darryl Jones, Implant's former Vice President, Global Sales and Marketing, has been promoted to Executive Vice President, Global Sales, Marketing, Technical Service and Business Development.
Mr. Silvestri joined Implant Sciences in September 2008 to lead the company's product development and certification process. Under his leadership, Implant Sciences' QS-B220 Desktop Explosives Trace Detector was successfully launched in 2010 and has been certified by the TSA, ECAC, CAAC and other worldwide organizations. Through that process, Mr. Silvestri has built a highly skilled team of scientists and design engineers, focused around Ion Mobility Spectrometry and Mass Spectroscopy technologies at Implant Sciences. Mr. Silvestri holds a Master's Degree in Business from the Kellogg School of Management at Northwestern University, as well as a BS in Chemical Engineering from Clarkson University.
Having joined Implant Sciences in May 2012, Dr. Jones brings significant homeland security industry experience to the company's sales and marketing efforts. Through his leadership, Implant Sciences successfully won the November 2014 contract from the U.S. Transportation Security Administration (TSA) for 1,170 QS-B220 systems, as well as approximately 900 systems in Europe over the past six months as a part of new airport screening regulations. He was previously Vice President of Global Product Management at Safran's Morpho Detection, where he managed one of the largest ETD and EDS product portfolios in the industry. Dr. Jones is a patent and scientific publications author, having received his PhD in Optical Science and Engineering from the University of Alabama, and a Masters of Arts and Bachelor of Arts in Physics from Fisk University.
"Todd and Darryl have been integral components to our growth over the past few years and we are excited about their new positions," stated Dr. Bill McGann, CEO of Implant Sciences. "As COO, Todd will provide company-wide leadership, management and vision, as he continues to increase efficiency across all aspects of operation. He will also continue to help mold the shape and objectives of our company as well as our commitment to our customers."
Dr. McGann continued, "By galvanizing our employees and executing a well thought out strategy, Darryl has proven himself to be an extremely effective sales and marketing leader. We believe that Darryl's performance and considerable industry experience will compliment Bob Liscouski's strategic business development efforts and greatly enhance our ability to form global industry partnerships to drive the company's growth."
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 70 countries worldwide. The Company's ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., ECAC in Europe, CAAC and the Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the Interior. It has also received the 2015 GSN Airport/Seaport/Border Security Award for "Best Security Checkpoint". All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and any statements of employees, representatives and partners of Implant Sciences Corporation (the "Company") related thereto contain or may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. Such statements are based on management's current expectations and are subject to significant risks and uncertainties (many of which are beyond the Company's control) that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks associated with the executive promotions described herein, the risk that there is no guaranty that the Transportation Security Administration (TSA) or any other U.S. or foreign government and law enforcement agencies or commercial consumers will purchase any of our explosives detection products or that any new products we may develop will be accepted by the TSA or by such other governments, agencies or consumers; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our ability to generate revenue and profit will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. In light of these risks and uncertainties, readers are cautioned that actual results may differ significantly from those described or anticipated in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
Implant Sciences Corporation
978-752-1700 x 116
SOURCE Implant Sciences Corporation